How Bowman V. Monsanto May Wreak Havoc On Biotechnology

Law360, New York (April 15, 2013, 1:03 PM EDT) -- On Feb. 19, 2013, the U.S. Supreme Court heard oral argument in Bowman v. Monsanto Company, a case involving the applicability of patent exhaustion to replicating technologies. The U.S. Supreme Court’s decision (likely to be issued by June) has the potential to have enormous impact on any life sciences company who makes, sells, uses or purchases self-replicating biotechnology (e.g., bacteria, cell lines, plasmids, microorganisms, synthetic molecules and other human-made living organisms) for research, diagnostic testing and/or industrial scale manufacturing.

The case dates back to Oct. 12,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.